Sfoglia per AUTORE
MACé S
Collezione AOU Città della Salute di Torino

  

Items : 6

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2025 Feb 18:JCO2401253. doi: 10.1200/JCO-24-01253.
2025
AOU Città della Salute di Torino

Kaiser MF; Sonneveld P; Cairns DA; Raab MS; San-Miguel Izquierdo J; Zhang R; Acosta J; Larocca A; Popat R; Li C; Baertsch MA; Brown SR; Lahuerta Palacios J; Gandhi AK; Macé S; Musto P; Yong K; Mai EK; Dubin F; Blade J; Capra A; Cook G; Bertsch U; Mateos MV; Boccadoro M; Jackson GH; Gutiérrez NC; Gay F; Weinhold N; et alii...

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. in Blood cancer journal / Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w.
2024
AOU Città della Salute di Torino

Richardson PG; Perrot A; Mikhael J; Martin T; Beksac M; Spicka I; Capra M; D'Agostino M; Sonneveld P; Bisht K; Fukao T; Zhang R; Tada K; Tekle C; Macé S; Klippel Z; van de Velde H; Moreau P;

2023
AOU Città della Salute di Torino

Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P;

2023
AOU Città della Salute di Torino

Ocio EM; Bringhen S; Martinez-Lopez J; San-Miguel J; Oliva S; Rodriguez-Otero P; Le Roux N; Dong Y; Doroumian S; Macé S; Mateos MV;

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. in Blood / Blood. 2021 Mar 4;137(9):1154-1165. doi: 10.1182/blood.2020008209.
2021
AOU Città della Salute di Torino

Anttila P; Capra M; Bringhen S; Dimopoulos M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R;

Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. in Future oncology (London, England) / Future Oncol. 2021 Dec;17(34):4797-4812. doi: 10.2217/fon-2021-0568. Epub 2021 Sep 15.
2021
AOU Città della Salute di Torino

Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA;